Literature DB >> 11303964

A population approach to enzyme characterization and identification: application to phenacetin O-deethylation.

D J Belle1, B J Ring, S R Allerheiligen, M A Heathman, L M O'Brien, V Sinha, L K Roskos, S A Wrighton.   

Abstract

PURPOSE: To determine the enzyme kinetics (EK) and identify the human cytochrome(s) P450 (CYP) involved in the deethylation of phenacetin to acetaminophen using a population-based method.
METHODS: A sparse data set was generated from incubations containing human liver microsomes (n = 19) with phenacetin. Estimates of the EK parameters were obtained by fitting the concentration-velocity data to Michaelis-Menten models by using nonlinear mixed effects modeling. Relationships between the EK parameters and the CYP activities determined for these liver microsomes were examined.
RESULTS: A two-enzyme kinetic model with a saturated, low KM enzyme and an unsaturated, high KM enzyme capable of forming acetaminophen best fit the data. The population estimates of the EK parameters were Vmax1, 911 pmol/min/mg protein; KM1, 11.3 microM; and Cl(int2), 0.4 microl/min/mg. The coefficients of variation for interliver variability in Vmax1 and residual error of the model were 39% and 15%, respectively. When the selective catalytic activities were examined as potential covariates, 7-ethoxyresorufin O-deethylation (CYP1A2) activity was found to be associated with the low KM enzyme, however, the high KM enzyme(s) could not be identified.
CONCLUSIONS: The population approach characterized the EK parameters and identified the low KM enzyme responsible for phenacetin O-deethylation as CYP1A2. Population modeling of EK provides valuable information on inter- and intraliver variability in CYP dependent activities.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11303964     DOI: 10.1023/a:1007665310830

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  14 in total

1.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

2.  Further characterization of the expression in liver and catalytic activity of CYP2B6.

Authors:  S Ekins; M Vandenbranden; B J Ring; J S Gillespie; T J Yang; H V Gelboin; S A Wrighton
Journal:  J Pharmacol Exp Ther       Date:  1998-09       Impact factor: 4.030

3.  Estimation of population characteristics of pharmacokinetic parameters from routine clinical data.

Authors:  L B Sheiner; B Rosenberg; V V Marathe
Journal:  J Pharmacokinet Biopharm       Date:  1977-10

4.  Characterization of AUCs from sparsely sampled populations in toxicology studies.

Authors:  S M Pai; S H Fettner; G Hajian; M N Cayen; V K Batra
Journal:  Pharm Res       Date:  1996-09       Impact factor: 4.200

Review 5.  Concomitant toxicokinetics: techniques for and interpretation of exposure data obtained during the conduct of toxicology studies.

Authors:  A M Dahlem; S R Allerheiligen; M J Vodicnik
Journal:  Toxicol Pathol       Date:  1995 Mar-Apr       Impact factor: 1.902

6.  Effect of fluoxetine, norfluoxetine, sertraline and desmethyl sertraline on human CYP3A catalyzed 1'-hydroxy midazolam formation in vitro.

Authors:  B J Ring; S N Binkley; L Roskos; S A Wrighton
Journal:  J Pharmacol Exp Ther       Date:  1995-12       Impact factor: 4.030

Review 7.  In vitro methods for assessing human hepatic drug metabolism: their use in drug development.

Authors:  S A Wrighton; M Vandenbranden; J C Stevens; L A Shipley; B J Ring; A E Rettie; J R Cashman
Journal:  Drug Metab Rev       Date:  1993       Impact factor: 4.518

8.  Phenacetin O-deethylation by human liver microsomes in vitro: inhibition by chemical probes, SSRI antidepressants, nefazodone and venlafaxine.

Authors:  L L von Moltke; D J Greenblatt; S X Duan; J Schmider; L Kudchadker; S M Fogelman; J S Harmatz; R I Shader
Journal:  Psychopharmacology (Berl)       Date:  1996-12       Impact factor: 4.530

9.  Isoform-selective mechanism-based inhibition of human cytochrome P450 1A2 by furafylline.

Authors:  K L Kunze; W F Trager
Journal:  Chem Res Toxicol       Date:  1993 Sep-Oct       Impact factor: 3.739

10.  Cytochrome P450TB (CYP2C): a major monooxygenase catalyzing diclofenac 4'-hydroxylation in human liver.

Authors:  T Leemann; C Transon; P Dayer
Journal:  Life Sci       Date:  1993       Impact factor: 5.037

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.